Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead’s Letairis Label Updated For Fluid Retention

This article was originally published in The Pink Sheet Daily

Executive Summary

Language similar to wording on competitor Tracleer.

You may also be interested in...



Actelion’s Tracleer Hangs On Against Label-Dampened Letairis

Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.

Actelion’s Tracleer Hangs On Against Label-Dampened Letairis

Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.

Encysive Rules Out FDA Dispute Resolution Path For Thelin NDA

Firm expects to have 35 sales reps for European, Canadian launch of Thelin by early next year, CEO says.

Topics

Latest News
UsernamePublicRestriction

Register

PS067266

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel